Aboleris Pharma bags €27.3m in Series A Financing

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

AbolerIS Pharma SA’s financing was led by  Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and RelyensInnovation Santé/Turenne Capital. Proceeds from the financing will enable AbolerIS to advance the development of its anti-CD45RC antibody treatment for rheumatoid arthritis to clinical stage and explore its efficacy in additional autoimmune diseases.

CD45RC is expressed on a subset of T cells that acts upstream of anti-inflammatory cytokine effectors by eliminating autoreactive effector T cells, increasing the relative ratio of regulatory T cells(Tregs), sparing memory T cells, and inducing immune tolerance. AbolerIS’ therapeutic strategy is to rebalance the immune system and prevent it from attacking the body’s own cells, which are at the root of multiple chronic autoimmune diseases.

Central to AbolerIS’ innovation lies the work of co-founders, Dr. Ignacio Anegon (Director of Research INSERM), and Dr. Carole Guillonneau, (Director of Research CNRS), both researchers in the Center of Research in Transplantation and Translational Immunology (CR2TI) UMR1064 INSERM/University of Nantes located at the Nantes University Hospital.